Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-T-lymphocyte antibodies and Gram-negative sepsis

Bone Marrow Transplantation

Volumn 32, Issue 9, 2003, Pages 941-945

  Dornbusch, Hans Juergen ^a   Strenger, V ^a   Kerbl, R ^a   Lackner, H ^a   Schwinger, W ^a   Sovinz, P ^a   Urban, C ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Antilymphocyte antibodies; CRP; Fever; Procalcitonin; Sepsis

Indexed keywords

BIOLOGICAL MARKER; BUSULFAN; C REACTIVE PROTEIN; CILASTATIN PLUS IMIPENEM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; MEROPENEM; MONOCLONAL ANTIBODY; NETILMICIN; OKT 3; POLYCLONAL ANTIBODY; PROCALCITONIN; T LYMPHOCYTE ANTIBODY; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APLASTIC ANEMIA; ARTICLE; BLOOD CULTURE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE SEPSIS; HUMAN; IMMUNOLOGICAL PARAMETERS; INFANT; LYMPHOMA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

ADOLESCENT; ANTIBODIES; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FEVER; GRAM-NEGATIVE BACTERIA; HUMANS; INFANT; MALE; NEOPLASMS; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; SEPSIS; T-LYMPHOCYTES;

EID: 0242551702     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704265     Document Type: Article

References (13)

1. Dearden C, Foukaneli T, Lee P et al. The incidence and significance of fevers during treatment with antithymocyte globulin for aplastic anaemia. Br J Haematol 1998; 103: 846-848.
2. Peltola H, Jaakkola M. C-reactive protein in early detection of bacteremic versus viral infections in immunocompetent and compromised children. J Pediatr 1988; 113: 641-646.
3. Legouffe E, Rodriguez C, Picot MC et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leukemia Lymphoma 1998; 31: 351-357.
4. Dornbusch HJ, Kerbl R, Lackner H et al. Procalcitonin and C-reactive protein levels at the time of engraftment after stem cell transplantation. Acta Chir Austr 2000; 32: 37 (abstract P38).
5. Assicot M, Gendrel D, Carsin H et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993: 341: 515-518.
6. Fleischhack G, Kambeck I, Cipic D et al. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin-6, interleukin-8, soluble interleukin-2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 2000; 111: 1093-1102.
7. Nijsten MW, Olinga P, The TH et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000; 28: 458-461.
8. Lacour AG, Gervaix A, Zamora SA et al. Procalcitonin, IL-6, IL-8, IL-1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr 2001; 160: 95-100.
9. Kuse ER, Jaeger K. Procalcitonin increase after anti-CD3 monoclonal antibody therapy does not indicate infectious disease. Transplant Int 2001; 14: 55 (letter).
10. Sabat R, Hoflich C, Docke WD et al. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intens Care Med 2001; 27: 987-991.
11. Eberhard OK, Langefeld I, Kuse ER et al. Procalcitonin in the early phase after renal transplantation - will it add to diagnostic accuracy? Clin Transplant 1998; 12: 206-211.
12. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
13. Hayden WR. Sepsis terminology in pediatrics. J Pediatr 1994; 124: 657-658.